Amneal Pharmaceuticals, Inc. (AMRX)
Last updated: 2026-11-19 04:08:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Summary
Amneal Pharmaceuticals, Inc. (AMRX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $21.89, with a market capitalization of $7.40B and a P/E ratio of 55.20. Over the past 52 weeks, its price has ranged from $11.39 to $22.12. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$7.40B | |
$21.07 | |
$22.12 | |
$20.94 | |
$21.12 | |
1.53M | |
3.17M | |
55.20 | |
$22.12 | |
$11.39 | |
-- | |
2026-09-30 |
Amneal Pharmaceuticals, Inc. (AMRX) Latest Closing Stock Price
Amneal Pharmaceuticals, Inc. (AMRX) last closed at $21.89 as of 2026-11-19 00:58:00, up 3.67% ($0.77) from the previous close of $21.12.
During the latest regular trading session, AMRX traded between $20.94 and $22.12, with a volume of 1.53M shares. The closing price was near the upper end and near the upper end of its 52-week range.
Amneal Pharmaceuticals, Inc. (AMRX) 7-Day Stock Price Change
Over the past seven days, Amneal Pharmaceuticals, Inc. (AMRX) moved from $21.28 to $21.89, representing a gain of 2.86% ($0.61).
The stock traded between $20.29 and $22.12 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 2.11 million shares, down versus the previous seven-day period, indicating lower trading activity.
AMRX 52-Week Price Position
Position in Range: 97.8%
AMRX is currently trading at $21.89, placing it 97.8% of the way from its 52-week low of $11.39 to its 52-week high of $22.12. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Amneal Pharmaceuticals, Inc. (AMRX)?
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
Amneal Pharmaceuticals, Inc. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 8,500 |
| Exchange | NASDAQ |
| Company Website |
AMRX News
Latest news related to Amneal Pharmaceuticals, Inc. and AMRX stock.
- Read Full Article
- Read Full Article
'UK Drugmaker in Talks to Boost Estrogen Patch Supply in US' - Bloomberg
https://www.bloomberg.com/news/articles/2026-11-16/uk-drugmaker-in-talks-to-boost-estrogen-patch-supply-in-us
- Read Full Article
Here's Why You Should Add AURA Stock to Your Portfolio Now
Aura Biosciences completed enrollment and dosing in its phase III CoMpass study evaluating bel-sar for early choroidal melanoma treatment. Top-line data is expected in the second half of 2027. If successful, bel-sar could become the first FDA-approved frontline vision-preserving therapy for this indication. The company is also exploring bel-sar for choroidal metastases and ocular surface cancers, with updates expected in Q1 2027. AURA shares have risen 39.6% year-to-date.
- Read Full Article
Zoetis' Cytopoint Plus Gets USDA License for 75-Day Canine Itch Relief
Zoetis announced USDA approval for Cytopoint Plus, a monoclonal antibody therapy providing 75 days of relief from allergic itch in dogs. The extended dosing interval is approximately 1.5 times longer than existing mAb options, expanding Zoetis' canine dermatology portfolio alongside Cytopoint, Apoquel, and Apoquel Chewable. Market uptake will depend on pricing, veterinary recommendations, and real-world performance.
- Read Full Article
BEAM Stock Falls 7% Despite Meeting Primary Endpoints in SCD Study
Beam Therapeutics reported positive top-line results from its BEACON study for risto-cel, a gene-editing therapy for sickle cell disease, achieving primary efficacy and safety endpoints with patients demonstrating freedom from severe vaso-occlusive crises for at least 12 consecutive months. The company plans to submit a biologics license application to the FDA by end of 2026, potentially marking the first commercial product approval for a base-editing therapy. Despite the encouraging clinical results, BEAM shares declined 7% following the announcement, likely due to concerns over weaker third-quarter results and profit-taking.
Ways to Trade AMRX at MEXC
How to Buy Amneal Pharmaceuticals, Inc. (AMRX) Stock on MEXC
Eligible investors can buy real shares of Amneal Pharmaceuticals, Inc. (AMRX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Amneal Pharmaceuticals, Inc. (AMRX) stock price today?
2.Is AMRX stock going up or down today?
3.What is AMRX pre-market price?
4.What is AMRX after-hours price?
5.Is AMRX stock trading now?
6.Where does AMRX sit relative to its 52-week high and low?
7.What sector is Amneal Pharmaceuticals, Inc. in?
8.What is Amneal Pharmaceuticals, Inc.'s market capitalization and where is it listed?
9.How is AMRX valued in terms of P/E ratio and EPS?
10.Does Amneal Pharmaceuticals, Inc. pay a dividend?
Explore More US Stocks
Compliance Disclosure and Data Source
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to AMRX, including Stocks, Tokenized Stocks, and Stock Futures.
Disclaimer
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Search Stocks
AMRX Stock Calculator
Estimate the value between AMRX shares and USD.
AMRX Shares to USD
1.00 AMRX shares = 21.889 USD
Calculations are estimates based on the latest available price and are for reference only.


